Blood Based Biomarkers Market Report 2026

The blood based biomarkers market size has grown rapidly in recent years. It will grow from $25.83 billion in 2025 to $28.94 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to advances in molecular diagnostics, cancer screening programs, biomarker validation studies, hospital diagnostic infrastructure, research funding growth.

The blood based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $45.5 billion in 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to liquid biopsy expansion, AI-powered biomarker analytics, chronic disease monitoring demand, personalized medicine adoption, point-of-care testing growth. Major trends in the forecast period include growing adoption of non-invasive diagnostics, expansion of precision oncology applications, increased use in early disease detection, rising demand for personalized treatment monitoring, integration with clinical decision support systems.

The rising incidence of cardiovascular diseases is expected to drive the growth of the blood-based biomarkers market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. This increase is largely driven by risk factors such as poor diet and rising obesity rates. Blood-based biomarkers assist in diagnosing and monitoring cardiovascular diseases by providing measurable indicators in the blood that reflect disease progression, assess risk, and guide treatment response. For example, in September 2024, the National Center for Biotechnology Information, a US-based government agency, reported projections from a global health research initiative indicating a 90% rise in cardiovascular disease prevalence between 2025 and 2050, with cardiovascular-related deaths expected to reach 35.6 million by 2050. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the blood-based biomarkers market.

Leading companies in the blood-based biomarkers market are focusing on technological advancements, such as high-accuracy blood biomarker tests, to assist physicians in diagnosing Alzheimer’s disease. High-accuracy blood biomarker tests are diagnostic tools that measure specific biomarkers in the blood to detect diseases or monitor health conditions with a high degree of precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, launched LucentAD p-Tau 217, a high-accuracy blood biomarker test designed to aid physicians in diagnosing Alzheimer’s disease (AD) in adults with cognitive impairment. The test measures phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker closely linked to AD pathology, particularly amyloid buildup in the brain. LucentAD p-Tau 217 achieves over 90% accuracy, meeting rigorous diagnostic standards, and is intended for use alongside other diagnostic tools rather than as a standalone test.

In December 2023, Danaher, a US-based provider of diagnostic, life sciences, and environmental solutions, acquired Abcam for $5.7 billion. Through this acquisition, Danaher aims to expand its portfolio of life sciences products and services by incorporating Abcam’s leading protein consumables and research tools. Abcam, based in the UK, specializes in the development and distribution of life sciences research tools, including antibodies, assays, and reagents.

Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG.

North America was the largest region in the blood-based biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood based biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the blood based biomarkers market by increasing the cost of imported diagnostic reagents, testing kits, and analytical instruments. These impacts have been most pronounced in genetic and protein biomarker segments, particularly in north america and europe where advanced diagnostics rely on global sourcing. Asia-pacific laboratories have experienced equipment pricing pressures. However, tariffs have encouraged domestic manufacturing of diagnostic reagents and testing platforms.

The blood based biomarkers market research report is one of a series of new reports that provides blood based biomarkers market statistics, including blood based biomarkers industry global market size, regional shares, competitors with a blood based biomarkers market share, detailed blood based biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the blood based biomarkers industry. This blood based biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood-based biomarkers are measurable substances in the blood that indicate the presence or progression of a disease and an individual’s response to treatment. Their primary role is to enable early disease detection, guide personalized treatment decisions, and monitor therapeutic efficacy with minimal invasiveness.

The main types of blood-based biomarkers include genetic, protein, metabolic, cell-based, and epigenetic biomarkers. Genetic biomarkers, based on DNA or RNA, reveal genetic variations, mutations, or expression patterns linked to specific diseases or treatment responses. These biomarkers are utilized with technologies such as next-generation sequencing, polymerase chain reaction, immunoassays, mass spectrometry, and other advanced methods. They are applied in diagnosing and monitoring conditions including cancer, cardiovascular diseases, neurological disorders, immunological diseases, and more. Key end users include hospitals and clinics, diagnostic laboratories, research and academic institutes, and other healthcare facilities.

The blood-based biomarkers market consists of revenues earned by entities by providing services such as clinical trial services, sample collection and biobanking services, custom biomarker assay development, data analysis and interpretation services, companion diagnostics services, point-of-care testing services, and regulatory and compliance support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood-based biomarkers market includes sales of diagnostic kits, reagents, assay platforms, analyzers, and related consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.